Original Article
Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study
Ilteris Oguz Topala,
, Sevim Baysakb, İlknur Kıvanç Altunayc, Asude Kara Polatd, Eylem Emel Arıkane, Ezgi Özkurc, Sema Aytekinf, Bilal Doganb, Tuğba Özkök Akbulutg, Filiz Topaloğlu Demirh, Ayşe Serap Karadaği
Corresponding author
a Department of Dermatology and Venereology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey
b Department of Dermatology and Venereology, University of Health Sciences, Sultan II. Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
c Department of Dermatology and Venereology, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
d Department of Dermatology and Venereology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey
e Department of Dermatology and Venereology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey
f Department of Dermatology and Venereology, University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey
g Department of Dermatology and Venereology, University of Health Sciences, Haseki Training and Research Hospital, Istanbul, Turkey
h Department of Dermatology and Venereology, Istanbul Medipol University, Faculty of Medicine, Istanbul, Turkey
i Department of Dermatology and Venereology, Memorial Atasehir Hospital, Turkey
Ver másRead
7771
Timeswas read the article
2852
Total PDF
4919
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 11 | 86 | 40 | 126 |
| 2025 10 | 251 | 155 | 406 |
| 2025 9 | 210 | 104 | 314 |
| 2025 8 | 158 | 65 | 223 |
| 2025 7 | 216 | 85 | 301 |
| 2025 6 | 217 | 91 | 308 |
| 2025 5 | 160 | 65 | 225 |
| 2025 4 | 186 | 64 | 250 |
| 2025 3 | 198 | 49 | 247 |
| 2025 2 | 138 | 71 | 209 |
| 2025 1 | 140 | 65 | 205 |
| 2024 12 | 123 | 50 | 173 |
| 2024 11 | 122 | 52 | 174 |
| 2024 10 | 129 | 85 | 214 |
| 2024 9 | 167 | 94 | 261 |
| 2024 8 | 181 | 126 | 307 |
| 2024 7 | 165 | 111 | 276 |
| 2024 6 | 133 | 77 | 210 |
| 2024 5 | 135 | 73 | 208 |
| 2024 4 | 98 | 95 | 193 |
| 2024 3 | 81 | 72 | 153 |
| 2024 2 | 90 | 80 | 170 |
| 2024 1 | 120 | 57 | 177 |
| 2023 12 | 69 | 63 | 132 |
| 2023 11 | 81 | 101 | 182 |
| 2023 10 | 59 | 84 | 143 |
| 2023 9 | 75 | 81 | 156 |
| 2023 8 | 80 | 35 | 115 |
| 2023 7 | 77 | 36 | 113 |
| 2023 6 | 66 | 46 | 112 |
| 2023 5 | 64 | 36 | 100 |
| 2023 4 | 37 | 14 | 51 |
| 2023 3 | 81 | 56 | 137 |
| 2023 2 | 62 | 29 | 91 |
| 2023 1 | 87 | 41 | 128 |
| 2022 12 | 106 | 53 | 159 |
| 2022 11 | 96 | 63 | 159 |
| 2022 10 | 114 | 85 | 199 |
| 2022 9 | 157 | 86 | 243 |
| 2022 8 | 66 | 65 | 131 |
| 2022 7 | 38 | 52 | 90 |
Show all
